TxCell hires Lentigen to make vectors used to produce its organ rejection cell therapy

By Gareth Macdonald

- Last updated on GMT


Related tags Cell therapy

TxCell SA has hired Lentigen Technology Inc. to make the vectors it uses to make its T-cell transplant rejection therapy.

The deal – financial terms of which were not disclosed – Lentigen make HLA‑A2 CAR lentiviral vector for the production of CAR-Treg transplantation (ENTX#SOT), a cell therapy TxCell is developing with the University of British Columbia.

ENTX#SOT is designed to prevent graft-versus-host disease after transplantation. It was developed using TxCell’s ENTrIA platform which uses chimeric antigen receptors (CARs) to direct antigen-specific regulatory cells (Ag-Tregs) to target autoimmune diseases.

The cell therapy is due to enter first-in-man studies at the end of next year​.

Lentigen – which is owned by Miltenyi Biotec GmbH​ – will make HLA-A2 CAR lentiviral vectors batches for the trials. It will also make vectors for planned preclinical studies.

TxCell is looking for a second contract manufacturing organisation (CMO) to use the vectors to produce ENTX#SOT.

The French biotechnology firm said it is developing a manufacturing process for CAR‑Treg cells and expects to start the technology transfer to the selected CMO by the end of the year.

TxCell has previously announced deals with Belgian CMO MaSTherCell​ and US contractor PCT​, a subsidiary of Caladrius Biosciences, both of which focused on the manufacture of its – which made the T-cell Crohn’s disease therapy, Ovasave.

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers